Abstract
It is known that tumor cells adapt characteristic metabolic phenotypes during cancer initiation and progression. The hallmark of tumor metabolism is aerobic glycolysis, or Warburg Effect, which was first described more than 80 years ago. Unlike normal cells, most cancer cells produce energy by a high rate of glycolic catabolism to lactate in the cytosol, rather than by oxidation of pyruvate in mitochondria, even in the presence of oxygen. Progress over the past decade has revealed that alterations of oncogenes and tumor suppressors are responsible for such metabolic reprogramming in cancer cells, however, the underlying molecular basis remains largely unknown. Mounting evidence shows the interplay between microRNAs and oncogenes/tumor suppressors, via key metabolic enzyme effecters, which could facilitate the Warburg Effect in cancer cells. In this review, we will summarize our current understanding of the roles of microRNAs, in particular their interplay with oncogenes/tumor suppressors such as cMyc, HIF-1 and P53, in tumor metabolism.
Keywords: cMyc, HIF-1, miRNA, P53, tumor metabolism, Warburg effect.
Current Gene Therapy
Title:MicroRNAs and the Warburg Effect: New Players in an Old Arena
Volume: 12 Issue: 4
Author(s): Ping Gao, Linchong Sun, Xiaoping He, Yang Cao and Huafeng Zhang
Affiliation:
Keywords: cMyc, HIF-1, miRNA, P53, tumor metabolism, Warburg effect.
Abstract: It is known that tumor cells adapt characteristic metabolic phenotypes during cancer initiation and progression. The hallmark of tumor metabolism is aerobic glycolysis, or Warburg Effect, which was first described more than 80 years ago. Unlike normal cells, most cancer cells produce energy by a high rate of glycolic catabolism to lactate in the cytosol, rather than by oxidation of pyruvate in mitochondria, even in the presence of oxygen. Progress over the past decade has revealed that alterations of oncogenes and tumor suppressors are responsible for such metabolic reprogramming in cancer cells, however, the underlying molecular basis remains largely unknown. Mounting evidence shows the interplay between microRNAs and oncogenes/tumor suppressors, via key metabolic enzyme effecters, which could facilitate the Warburg Effect in cancer cells. In this review, we will summarize our current understanding of the roles of microRNAs, in particular their interplay with oncogenes/tumor suppressors such as cMyc, HIF-1 and P53, in tumor metabolism.
Export Options
About this article
Cite this article as:
Gao Ping, Sun Linchong, He Xiaoping, Cao Yang and Zhang Huafeng, MicroRNAs and the Warburg Effect: New Players in an Old Arena, Current Gene Therapy 2012; 12 (4) . https://dx.doi.org/10.2174/156652312802083620
DOI https://dx.doi.org/10.2174/156652312802083620 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Integral Nuclear Membrane Protein Nurim Plays a Role in the Suppression of Apoptosis
Current Molecular Medicine Nanoparticles for Gene Delivery: A Brief Patent Review
Recent Patents on Drug Delivery & Formulation “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters Preformulation Designed to Enable Discovery and Assess Developability
Combinatorial Chemistry & High Throughput Screening Patent Selections
Recent Patents on Regenerative Medicine Elucidation of the Chemopreventive Role of Stigmasterol Against Jab1 in Gall Bladder Carcinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Roles of Calcium and Tyrosine Kinases in the Pathogenesis of Type 2 Diabetes Mellitus
Current Enzyme Inhibition Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Current Vascular Pharmacology The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Current Status and Future Perspectives of Chemoprevention in Head and Neck Cancer
Current Cancer Drug Targets Comprehensive Profile of <i>Madhuca Longifolia</i> in Pharma and Food Industry
Current Nutraceuticals Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry Relevance of Micrometastases and Targeting the Bone Marrow Niche with Zoledronic Acid in Breast Cancer
Current Cancer Therapy Reviews An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis
MicroRNA Ovarian Granulosa Cell Tumor: A Clinicoradiologic Series with Literature Review
Current Medical Imaging The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH
Current Drug Targets Renal & Ocular Targets for Therapy in Wegeners Granulomatosis
Inflammation & Allergy - Drug Targets (Discontinued) Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets